ImmunityBio Quickly Fixes FDA Ad Concerns: Podcast Pulled, TV Spot Never Aired
ImmunityBio addressed FDA ad concerns, removed a podcast, and clarified ANKTIVA info while tightening rules on future promotions.
/ 9 items
#IBRX↓
ImmunityBio Scores $100 Million Cash Boost – $75M Non-Dilutive – to Supercharge Global Expansion
ImmunityBio strengthens its balance sheet with $100 million financing, including $75M non-dilutive funding from Oberland Capital and $25M debt conversion.
FDA Slaps ImmunityBio with Warning Letter Over Misleading ANKTIVA Ads
ImmunityBio shares dropped 20% after the FDA issued a warning letter accusing the company of false claims that ANKTIVA cures all cancers.
ImmunityBio Builds the “World Bank of NK Cells”: 5 Billion Cancer-Fighting Cells from One Blood Draw in Just 12 Days
ImmunityBio just hit a huge milestone – they can now mass-produce and freeze powerful NK cells from healthy and cancer donors. One simple blood draw gives 8–10 ready-to-use doses.
Europe Approves ANKTIVA: First Immunotherapy for Hard-to-Treat Bladder Cancer Now in 33 Countries
ImmunityBio’s ANKTIVA + BCG just received European Commission approval – the first new immunotherapy in Europe for hard-to-treat bladder cancer. Now available in 33 countries, offering hope without surgery.
ImmunityBio Moves Forward with FDA on Bladder Cancer Treatment ANKTIVA
ImmunityBio advances FDA talks for ANKTIVA in papillary bladder cancer. Treatment shows 96% survival & 80% avoid bladder removal at 3 years, offering hope vs. current option: invasive surgery.